Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Keppel, MH; Piecha, G; März, W; Cadamuro, J; Auer, S; Felder, TK; Mrazek, C; Oberkofler, H; Trummer, C; Grübler, MR; Schwetz, V; Verheyen, N; Pandis, M; Borzan, V; Haschke-Becher, E; Tomaschitz, A; Pilz, S.
The endogenous cardiotonic steroid Marinobufagenin and decline in estimated glomerular filtration rate at follow-up in patients with arterial hypertension.
PLoS One. 2019; 14(2):e0212973 Doi: 10.1371/journal.pone.0212973 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG


Führende Autor*innen der Med Uni Graz
Keppel Martin
Co-Autor*innen der Med Uni Graz
Borzan Valentin
Grübler Martin
März Winfried
Pandis Marlene
Pilz Stefan
Theiler-Schwetz Verena
Tomaschitz Andreas
Trummer Christian
Verheyen Nicolas Dominik

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

BACKGROUND: Marinobufagenin (MBG) is an endogenous cardiotonic steroid (CTS) that inhibits the Na+/K+-ATPase. Human MBG is significantly increased in end-stage renal disease and immunization against MBG attenuates cardiovascular fibrosis in a rat model of uremic cardiomyopathy. Mineralocorticoid antagonists (MRA) block MBG binding sites and decrease proteinuria in chronic kidney disease (CKD) patients. We therefore aimed to investigate the association of MBG and albuminuria, as a marker of renal damage, as well as MBG and decline of glomerular filtration rate (GFR). METHODS: The Graz endocrine causes of hypertension (GECOH) study is a single center study of adults routinely referred for screening of endocrine hypertension. Plasma MBG was measured by an enzyme-linked immunoassay, and in a post-hoc analysis, follow-up creatinine levels were obtained. Patients with proteinuria >3.5g/day at baseline were excluded from further evaluation. RESULTS: We measured MBG concentrations in 40 hypertensive subjects and excluded one patient due to pre-existing proteinuria. Plasma MBG was significantly correlated with albuminuria (Spearman ρ = .357; p = .028) and proteinuria (ρ = .336; p = .039). In linear regression analysis, the association remained significant after adjustment for age, sex, and BMI (β = .306; p = .036), and for mean systolic blood pressure (β = .352; p = .034). In follow-up analyses (N = 30), MBG was significantly associated with decline in GFR after adjustment for time-to-follow-up (β = -.374; p = .042). CONCLUSION: The findings suggest that MBG plasma concentrations were associated with albuminuria as well as decline in kidney function. Whether MBG predicts hard renal endpoints warrants further investigations.
Find related publications in this database (using NLM MeSH Indexing)
Adult - administration & dosage
Aged - administration & dosage
Albuminuria - blood, physiopathology
Animals - administration & dosage
Biomarkers - blood
Bufanolides - blood
Cardiotonic Agents - blood
Enzyme Inhibitors - blood
Female - administration & dosage
Follow-Up Studies - administration & dosage
Glomerular Filtration Rate - physiology
Humans - administration & dosage
Hypertension - blood, physiopathology
Male - administration & dosage
Middle Aged - administration & dosage
Proteinuria - blood, physiopathology
Rats - administration & dosage
Renal Insufficiency, Chronic - blood, physiopathology

© Med Uni Graz Impressum